Literature DB >> 31917455

Polycystic Ovary Syndrome Signs and Metabolic Syndrome in Premenopausal Hispanic/Latina Women: the HCHS/SOL Study.

Michelle L Meyer1, Daniela Sotres-Alvarez2, Anne Z Steiner3, Larry Cousins4, Gregory A Talavera5, Jianwen Cai2, Martha L Daviglus6, Laura R Loehr7.   

Abstract

CONTEXT: Polycystic ovary syndrome (PCOS), a condition of androgen excess in women, is associated with cardiometabolic risk factors; however, this association is not fully characterized in a population-based sample of premenopausal women and high-risk groups such as Hispanics/Latinas.
OBJECTIVE: We examined the association of PCOS signs and metabolic syndrome (MetS) in premenopausal Hispanic/Latina women.
METHODS: This cross-sectional analysis includes 1427 women age 24 to 44 years from the Hispanic Community Health Study/Study of Latinos. PCOS signs included menstrual cycle greater than 35 days or irregular, self-reported PCOS, and oral contraceptive use to regulate periods or acne, and a composite of 1 or more PCOS signs. We calculated odds ratios (OR) and 95% CI for MetS, accounting for sociodemographic factors and the complex survey design; an additional model included body mass index (BMI).
RESULTS: The mean age was 34 years and 30% reported any PCOS sign. The odds of MetS were higher in women reporting cycles greater than 35 days or irregular (OR 1.63; CI: 1.07-2.49) vs cycles 24 to 35 days, self-reported PCOS (OR 2.49; CI: 1.38-4.50) vs no PCOS, and any PCOS sign (OR 1.58; CI: 1.10-2.26) vs none. We found no association between OC use to regulate periods or acne and MetS (OR 1.1; CI: 0.6-1.8). When adjusting for BMI, only the association of self-reported PCOS and MetS was attenuated (OR 1.78; CI: 0.92-3.44).
CONCLUSIONS: In Hispanic/Latina women, irregular menstrual cycles, self-reported PCOS, and any PCOS sign were associated with MetS and could indicate women at metabolic disease risk. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  androgen excess; cardiometabolic risk factors; polycystic ovary syndrome; testosterone; women’s health

Mesh:

Year:  2020        PMID: 31917455      PMCID: PMC7007876          DOI: 10.1210/clinem/dgaa012

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  44 in total

1.  Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome.

Authors:  Joan C Lo; Seth L Feigenbaum; Jingrong Yang; Alice R Pressman; Joe V Selby; Alan S Go
Journal:  J Clin Endocrinol Metab       Date:  2006-01-24       Impact factor: 5.958

2.  Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus.

Authors:  C G Solomon; F B Hu; A Dunaif; J Rich-Edwards; W C Willett; D J Hunter; G A Colditz; F E Speizer; J E Manson
Journal:  JAMA       Date:  2001-11-21       Impact factor: 56.272

Review 3.  Polycystic ovary syndrome: a changing perspective.

Authors:  S Franks
Journal:  Clin Endocrinol (Oxf)       Date:  1989-07       Impact factor: 3.478

4.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.

Authors:  Earl S Ford; Wayne H Giles; William H Dietz
Journal:  JAMA       Date:  2002-01-16       Impact factor: 56.272

5.  Sample design and cohort selection in the Hispanic Community Health Study/Study of Latinos.

Authors:  Lisa M Lavange; William D Kalsbeek; Paul D Sorlie; Larissa M Avilés-Santa; Robert C Kaplan; Janice Barnhart; Kiang Liu; Aida Giachello; David J Lee; John Ryan; Michael H Criqui; John P Elder
Journal:  Ann Epidemiol       Date:  2010-08       Impact factor: 3.797

6.  The severity of menstrual dysfunction as a predictor of insulin resistance in PCOS.

Authors:  Meredith Brower; Kathleen Brennan; Marita Pall; Ricardo Azziz
Journal:  J Clin Endocrinol Metab       Date:  2013-10-03       Impact factor: 5.958

7.  Glucose and insulin components of the metabolic syndrome are associated with hyperandrogenism in postmenopausal women: the atherosclerosis risk in communities study.

Authors:  Sherita Hill Golden; Jingzhong Ding; Moyses Szklo; Maria Ines Schmidt; Bruce B Duncan; Adrian Dobs
Journal:  Am J Epidemiol       Date:  2004-09-15       Impact factor: 4.897

8.  Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study.

Authors:  E S Knochenhauer; T J Key; M Kahsar-Miller; W Waggoner; L R Boots; R Azziz
Journal:  J Clin Endocrinol Metab       Date:  1998-09       Impact factor: 5.958

9.  The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria.

Authors:  Wendy A March; Vivienne M Moore; Kristyn J Willson; David I W Phillips; Robert J Norman; Michael J Davies
Journal:  Hum Reprod       Date:  2009-11-12       Impact factor: 6.918

Review 10.  The polycystic ovary syndrome: a position statement from the European Society of Endocrinology.

Authors:  Gerard Conway; Didier Dewailly; Evanthia Diamanti-Kandarakis; Héctor F Escobar-Morreale; Stephen Franks; Alessandra Gambineri; Fahrettin Kelestimur; Djuro Macut; Dragan Micic; Renato Pasquali; Marija Pfeifer; Duarte Pignatelli; Michel Pugeat; Bulent O Yildiz
Journal:  Eur J Endocrinol       Date:  2014-05-21       Impact factor: 6.664

View more
  2 in total

1.  Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome.

Authors:  U Ezeh; M D Pisarska; R Azziz
Journal:  Hum Reprod       Date:  2022-03-01       Impact factor: 6.918

2.  Characterizing the Clinical and Genetic Spectrum of Polycystic Ovary Syndrome in Electronic Health Records.

Authors:  Ky'Era V Actkins; Kritika Singh; Donald Hucks; Digna R Velez Edwards; Melinda Aldrich; Jeeyeon Cha; Melissa Wellons; Lea K Davis
Journal:  J Clin Endocrinol Metab       Date:  2021-01-01       Impact factor: 5.958

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.